Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a C

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary...

Related Keywords

Japan , Oklahoma , United States , Japanese , Joan Merrill , Roopal Thakkar , Upadacitinib Monotherapy , Linkedin , Arthritis Clinical Immunology Research Program , Centers For Disease , European Congress , Lupus Erythematosus National Assessment , Exchange Commission , Oklahoma Medical Research Foundation , Twitter , Facebook , Abbvie Deutschland Gmbh Co , Instagram , British Isles Lupus Assessment Group , Responder Index , Lupus Low Disease Activity State , Flare Index , Clinical Immunology Research , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Final Lock , Key Results , Intended Indication , Systemic Lupus Erythematosus , Adult Systemic Lupus Erythematosus , Disease Activity , Arthritis Care Res , Disease Control , Accessed April , Vie Deutschland Gmbh , Severely Active Ulcerative , Maintenance Therapy , Severely Active Ulcerative Colitis , Takayasu Arteritis , Evaluate Efficacy , Adult Participants , Ann Rheum , Giant Cell , Abbvie , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Biotechnology , Trade Show News , Clinical Trials Amp Medical Discoveries ,